The phase II study found that nivolumab was well tolerated and demonstrated moderate efficacy with durable response in patients with refractory biliary tract cancer.
A recent study implemented the Screen to Save program to educate racial/ethnic minority groups on colorectal cancer, finding that knowledge and screenings increased after patients completed the educational program.
Researchers found that a high dose of CAR T-19 may be more effective than a low dose at inducing a complete response without excessive toxicity.
The oncology hematologist spoke about the guidelines she and her colleagues outlined regarding treating patients with hematologic malignancies during the COVID-19 pandemic.
The combination of tavo and pembrolizumab was associated with a higher than anticipated response rate in patients with advanced melanoma with low frequencies of checkpoint positive cytotoxic lymphocytes.
Researchers found a steady increase in racial inequalities of the mortality rate from liver cancer from 1998-2016 after lifesaving drugs for hepatitis C virus were introduced.
Researchers found that 2 studied strategies, which combined nivolumab and doxorubicin, vinblastine, and dacarbazine, are feasible, highly effective, and result in excellent 12-month progression-free survival.
A clinically applicable mathematical model was developed by researchers to predict outcomes to immunotherapy for patients with cancer previously treated with anti–CTLA-4 or anti–PD-1/PD-L1 antibodies.
SGX301 is being evaluated for the treatment of patients with early-stage cutaneous T-cell lymphoma in the pivotal phase III FLASH study, which demonstrated that continued treatment twice weekly for 12 weeks increased the positive response rate.
The study, titled OLYMPUS, suggested that primary chemoablation of low-grade upper tract urothelial cancer with intracavitary UGN-101 resulted in clinically significant disease eradication.
Researchers indicated that targeted approaches to improving time from diagnosis to definitive surgery for black patients are essential in reducing racial disparities in melanoma outcomes.
This study analyzed the full prevalence and spectrum of partner and localizer BRCA2 (PALB2) germline mutations in China, focusing on the associations between these PALB2 germline mutations and breast cancer risk.
The FDA approved the first therapy to treat cancers with rearranged during transfection (RET) gene alterations.
The medical oncologist discussed reported outcomes of larotrectinib in patients with TRK fusion cancer by the number of lines of priory therapy or baseline status.
Recent data suggests that, while short delays beyond 5 weeks after surgical resection of glioblastoma did not negatively impact survival outcomes, early initiation of chemoradiation before 3 weeks could be detrimental to patients.